BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37437437)

  • 41. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
    Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
    Devaud N; Kanji ZS; Dhani N; Grant RC; Shoushtari H; Serrano PE; Nanji S; Greig PD; McGilvray I; Moulton CA; Wei A; Gallinger S; Cleary SP
    HPB (Oxford); 2014 May; 16(5):475-80. PubMed ID: 23927606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
    Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
    Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases.
    Imai K; Allard MA; Castro Benitez C; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Bismuth H; Baba H; Adam R
    Br J Surg; 2016 Apr; 103(5):590-9. PubMed ID: 26780341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
    Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S
    BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic value of fluorodeoxyglucose positron emission tomography metabolic tumor volume in solitary colorectal liver metastasis.
    Huang YT; Park J; Chong S; Hugh TJ; Ng WL; Lin M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e262-e270. PubMed ID: 27451967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection.
    Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J
    Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Ruers T; Van Coevorden F; Punt CJ; Pierie JE; Borel-Rinkes I; Ledermann JA; Poston G; Bechstein W; Lentz MA; Mauer M; Folprecht G; Van Cutsem E; Ducreux M; Nordlinger B; ; ; ;
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
    Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
    Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
    Dhir M; Jones HL; Shuai Y; Clifford AK; Perkins S; Steve J; Hogg ME; Choudry MH; Pingpank JF; Holtzman MP; Zeh HJ; Bahary N; Bartlett DL; Zureikat AH
    Ann Surg Oncol; 2017 Jan; 24(1):150-158. PubMed ID: 27431415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study.
    Grut H; Line PD; Syversveen T; Dueland S
    Ann Nucl Med; 2022 Dec; 36(12):1073-1081. PubMed ID: 36241941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
    Liang SB; Teng JJ; Hu XF; Yang XL; Luo M; Fang XN; Liu DS; Chen Y; Fu LW
    BMC Cancer; 2017 Jul; 17(1):506. PubMed ID: 28754109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Conversion therapy for synchronous colorectal liver metastases].
    Morohashi H; Yokoyama H; Akasaka H; Sakamoto Y; Koyama M; Murata A; Hakamada K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1665-7. PubMed ID: 24393882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing the selection of technically unresectable colorectal liver metastases.
    Kobayashi K; Inoue Y; Kitano Y; Sato S; Oba A; Ono Y; Sato T; Ito H; Mise Y; Saiura A; Takahashi Y
    Surgery; 2023 Feb; 173(2):442-449. PubMed ID: 36384649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.